BIGAS A. (0000-0003-4801-6899)

Personal information

Biography

Anna Bigas holds a PhD in Cell Biology from the University of Barcelona (1993). Dr. Bigas has a double affiliation with IMIM (since 2009) and IJC (starting 2020) and she is currently the Scientific Director of CIBERONC, a Spanish cancer virtual center for collaborative research.

She has a long-standing interest in hematopoietic stem cells and leukemogenesis. Her work as a post-doctoral fellow (Fred Hutchinson Cancer Research Center, Seattle 1993-1997) was pioneering in identifying a role of Notch in the regulating hematopoietic differentiation, a highly influential contribution to the field of hematopoiesis (PNAS 1996, Mol. Cell. Biol 1998).

Since starting her independent research group in Barcelona, Spain (IRO/IDIBELL, 1998-2008); she has sought to decipher the molecular mechanisms that regulate stem cell commitment, maintenance, differentiation and oncogenic transformation, mainly focused in the hematopoietic system, but also in the intestinal system. Through refined genetic studies her group has demonstrated crucial roles for Notch and Wnt in the generation of hematopoietic stem cells in the mouse embryo and her studies on Notch mechanisms have been highly influencial in the field (Development, 2005, EMBO J 2008, JEM 2012, 2013, 2014, Nat Comm 2015, EMBO J 2020).

In addition, her group has uncovered a role of Notch in regulating programmed cell death in erythroid lineages (Leukemia 2007), and the importance of Notch and other pathways in T-ALL and CTCL (Cancer Cell 2010, Leukemia 2016, Leukemia 2018) or intestinal development and cancer (PNAS 2009, Development 2015, Cancer Cell 2015). More recently, her work has focused in understanding mechanisms of resistance in both T-ALL (Genome Biology 2020, EMBO Mol Med 2023) and colorectal cancer (Mol Cell 2019, Nat Comm 2022).

Activities

Collapse all

Josep Carreras Leukaemia Research Institute: Barcelona, Cataluña, ES

2020-11-01 to present

Employment

BIGAS A.

https://orcid.org/0000-0003-4801-6899

Personal information

Websites & social links

Other IDs

Keywords

Countries

Biography

Activities

Employment (5)

Josep Carreras Leukaemia Research Institute: Barcelona, Cataluña, ES

Centro de Investigación Biomédica en Red de Cáncer: Madrid, Comunidad de Madrid, ES

Institut Hospital del Mar d'Investigacions Mèdiques: Barcelona, Catalunya, ES

Institut d'Investigacio Biomedica de Bellvitge: Barcelona, ES

Fred Hutchinson Cancer Research Center: Seattle, WA, US

Education and qualifications (1)

University of Barcelona: Barcelona, ES

Professional activities (4)

International Society for Experimental Hematology: Chicago, Illinois, US

European Hematology Association: Den Haag, Zuid-Holland, NL

ASOCIACIÓN ESPAÑOLA DE INVESTIGACIÓN SOBRE EL CÁNCER: Barcelona, ES

European Hematology Association: Den Haag, Zuid-Holland, NL

Works (50 of 155)

NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage

The interferon γ pathway enhances pluripotency and X-chromosome reactivation in iPSC reprogramming

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development

Cis inhibition of NOTCH1 through JAGGED1 sustains embryonic hematopoietic stem cell fate

UNCAN.eu: Toward a European Federated Cancer Research Data Hub

β-Catenin activity induces an RNA biosynthesis program promoting therapy resistance in T-cell acute lymphoblastic leukemia.

B- CATENIN ACTIVITY INDUCES AN RNA PROCESSING PROGRAM WITH IMPACT ON THERAPY RESISTANCE OF T CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target

Multiplex CRISPR/Cas9 Gene Editing in Human Stem Cells to Model Clonal Competition in GATA2 Deficiency

GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development

IκBα controls dormancy induction in Hematopoietic stem cell development via retinoic acid

Dissecting infant leukemia developmental origins with a hemogenic gastruloid model

IKKα kinase coordinates BRD4 and STAT3 signaling to subvert DNA damage-based anticancer therapy

Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.

Sézary syndrome patient-derived models allow drug selection for personalized therapy.

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis.

Recent advances in T-cell lymphoid neoplasms

The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells.

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.

Notch Signaling in HSC Emergence: When, Why and How

A novel role of MNT as a negative regulator of REL and the NF-κB pathway (vol 10, 7, 2021)

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

The EHA Research Roadmap: Normal Hematopoiesis.

Accumulation of Paneth Cells in Early Colorectal Adenomas Is Associated with Beta-Catenin Signaling and Poor Patient Prognosis

Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair

Dynamic chromatin association of IκBα is regulated by acetylation and cleavage of histone H4.

JEM career launchpad

A novel role of MNT as a negative regulator of REL and the NF-κB pathway.

CHARACTERIZATION OF ALTERNATIVE SPLICING DYNAMICS IN T-CELL MATURATION AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

FINE-TUNING GENE EXPRESSION BY CRISPRA IN MOUSE EMBRYONIC STEM CELLS FOR SPECIFIC TISSUE INDUCTION

IKBA IS REQUIRED FOR HSC GENERATION

INSIGHT ON NOTCH MECHANISMS TO ORCHESTRATE THE DEVELOPMENT OF HEMATOPOIETIC STEM CELLS IN THE EMBRYO

UNCOVERING THE B-CATENIN-DEPENDENT SIGNATURE IN T-CELL LEUKEMIA INITIATION AND MAINTENANCE

Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.

The evolution of relapse of adult T cell acute lymphoblastic leukemia.

Ancestral function of Inhibitors-of-kappaB regulates Caenorhabditis elegans development.

The Polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation.

Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells

IκBα deficiency imposes a fetal phenotype to intestinal stem cells

Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocation

Notch ligand Dll4 impairs cell recruitment to aortic clusters and limits blood stem cell generation.

Targeting IKKα kinase to prevent tumor progression and therapy resistance.

Revisiting β‐Catenin Signaling in T‐Cell Development and T‐Cell Acute Lymphoblastic Leukemia

NOTCH LIGAND DLL4 CONTROLS THE RECRUITMENT OF HEMOGENIC CELLS INTO THE INTRA-AORTIC CLUSTERS AND CONSEQUENTLY PRODUCTION OF HEMATOPOIETIC STEM CELLS

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between <i>AF4-MLL</i> and <i>MLL-AF4</i> fusions.

Blood Development: Hematopoietic Stem Cell Dependence and Independence

Establishment of an in vivo model of patient-derived SS for therapy validation

Peer review (55 reviews for 24 publications/grants)